BickD, JonesM, TaylorSL, et al. (2019) Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases. J Med Genet, 56:783-791.
2.
FarnaesL, HildrethA, SweeneyNM, et al. (2018) Rapid whole-genome sequencing decrease infant morbidity and cost of hospitalization. NPJ Genomic Med, 3:10.
3.
GonzaludoN, BelmontJW, GainullinVG, TaftRJ. (2019). Estimating the burden and economic impact of pediatric genetic disease. Genetics in Medicine, 21:1781-1789.
4.
HolmesMD, DalalS, VolminkJ, et al. (2010) Non-communicable diseases in sub-Saharan Africa: the case for cohort studies. PLoS Med, 7:e1000244.
5.
IncertiD. (2022) Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseases. Genet Med, 24:109-118.
6.
ScocchiaA, WigbyKM, Masser-FryeD, et al. (2019) Clinical whole genome sequencing as a first-tier test at a resource limited dysmorphology clinic in northern Mexico. NPJ Genom Med, 4:5.
7.
StarkZ, SchofieldD, MartynM, et al. (2019) Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness. Genet Med, 21:173-180.
8.
SweeneyNM, NahasSA, ChowdhuryS, et al. (2021) Rapid whole genome sequencing impacts care and resource utilization in infants with congenital heart disease. NPJ Genom Med, 6:29.
9.
WakapSN, LambertDM, OlryA, et al. (2020) Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet, 28:165-173.
10.
World Health Organization (2014) Noncommunicable Diseases Country Profiles 2014. Geneva: World Health Organization.
